Phase I/II study of AF802 in patients with Non-Small Cell Lung Cancer harboring ALK fusion gene

Trial Profile

Phase I/II study of AF802 in patients with Non-Small Cell Lung Cancer harboring ALK fusion gene

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Alectinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 15 Mar 2017 Results of three year follow-up data of phase II part of this study (n=46) published in the Journal of Clinical Oncology
    • 02 Jun 2015 Results of the phase II portion presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jul 2014 Status changed from active, no longer recruiting to completed according to a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top